HC Wainwright Forecasts Strong Price Appreciation for NRx Pharmaceuticals (NASDAQ:NRXP) Stock

NRx Pharmaceuticals (NASDAQ:NRXP) had its target price lifted by equities researchers at HC Wainwright from $40.00 to $45.00 in a report released on Tuesday, Marketbeat.com reports. The firm currently has a “buy” rating on the stock. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q3 2026 earnings at $0.03 EPS and FY2030 earnings at $6.15 EPS.

A number of other equities research analysts also recently issued reports on NRXP. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Zacks Research downgraded shares of NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. Ascendiant Capital Markets reaffirmed a “buy” rating and issued a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. BTIG Research reiterated a “buy” rating and issued a $25.00 price target on shares of NRx Pharmaceuticals in a research report on Wednesday, February 18th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, February 17th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

NRx Pharmaceuticals Price Performance

Shares of NRXP opened at $1.87 on Tuesday. The stock has a market capitalization of $59.60 million, a price-to-earnings ratio of -0.80 and a beta of 1.97. NRx Pharmaceuticals has a 1 year low of $1.58 and a 1 year high of $3.84. The business’s 50 day simple moving average is $2.11 and its 200-day simple moving average is $2.51.

Institutional Trading of NRx Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of NRXP. Geode Capital Management LLC lifted its position in shares of NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after purchasing an additional 37,598 shares during the last quarter. Ethos Financial Group LLC purchased a new position in NRx Pharmaceuticals in the 3rd quarter worth about $39,000. One Wealth Management Investment & Advisory Services LLC lifted its holdings in NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after buying an additional 12,950 shares in the last quarter. AdvisorShares Investments LLC boosted its position in NRx Pharmaceuticals by 29.7% in the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after buying an additional 78,339 shares during the period. Finally, Vanguard Group Inc. boosted its position in NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares during the period. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.